Genetic ablation and pharmacological inhibition of LRRK2 have previously been demonstrated to have a promising effect on disease relevant alterations in preclinical in vivo models of PD (Lin et al., 2009; Daher et al., 2014, 2015; Andersen et al., 2018a). The gene discussed is LRRK2; the disease is Parkinson disease.